Claims
- 1. A method for preventing or treating drug-induced nephrotoxicity in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 2. The method of claim 1, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.
- 3. The method of claim 1, wherein said composition comprises a controlled release formulation of said composition.
- 4. The method of claim 1, wherein said composition comprises a prodrug of said estradiol metabolite.
- 5. A method for preventing or treating drug-induced proteinuria in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 6. The method of claim 5, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.
- 7. The method of claim 5, wherein said composition comprises a controlled release formulation of said composition.
- 8. The method of claim 5, wherein said composition comprises a prodrug of said estradiol metabolite.
- 9. A method for preventing or treating drug-induced decreases in glomerlular filtration rate in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 10. The method of claim 9, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.
- 11. The method of claim 9, wherein said composition comprises a controlled release formulation of said comoposition.
- 12. The method of claim 9, wherein said composition comprises a prodrug of said estradiol metabolite.
- 13. A method for preventing or treating drug-induced infiltration of inflammatory cells into renal tissue in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 14. The method of claim 13, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.
- 15. The method of claim 13, wherein said composition comprises a controlled release formulation of said composition.
- 16. The method of claim 13, wherein said composition comprises a prodrug of said estradiol metabolite.
- 17. A method for preventing or treating drug-induced excessive proliferation of renal cells in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 18. The method of claim 17, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.
- 19. The method of claim 17, wherein said composition comprises a controlled release formulation of said composition.
- 20. The method of claim 17, wherein said composition comprises a prodrug of said estradiol metabolite.
- 21. A method for preventing or treating drug-induced excessive extracellular matrix protein production in renal tissue in an individual, comprising:
administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
- 22. The method of claim 21, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.
- 23. The method of claim 21, wherein said composition comprises a controlled release formulation of said composition.
- 24. The method of claim 21, wherein said composition comprises a prodrug of said estradiol metabolite.
RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Application No. 60/400,060 filed Aug. 2, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60400060 |
Aug 2002 |
US |